The American College of Cardiology announced the lineup of late-breaking clinical trials scheduled for presentation at its 2018 Scientific Session, including 21 late-breaking clinical trials and 17 featured clinical research trials.
Perhaps the most eagerly awaited study is ODYSSEY Outcomes, a trial to determine whether the PCSK9 inhibitor alirocumab (Praluent, Sanofi/Regeneron) can prevent CV events in high-risk patients when added to statin therapy.
The ACC Scientific Session will be held March 10-12 in Orlando, Florida.
According to a press release from the ACC, some of the other studies included in the five late-breaking clinical trial sessions will include:
- VEST, in which researchers studied the efficacy of a wearable cardioverter defibrillator (LifeVest, Zoll) after MI.
- PHARMCLO, which evaluates a pharmacogenomic approach to the selection of antiplatelet therapy in ACS.
- ARTEMIS, which studied the impact of patient copayment reduction on continued P2Y12 inhibitor use and clinical outcomes after MI.
- TREAT, designed to explore the safety and efficacy of ticagrelor (Brilinta, AstraZeneca) compared with clopidogrel in patients with ST-segment elevation ACS treated with thrombolysis.
- MANAGE, examining the effect of dabigatran (Pradaxa, Boehringer Ingelheim) in patients suffering myocardial injury after noncardiac surgery.
- SECURE-PCI, a trial of loading doses of atorvastatin vs. placebo in patients with ACS and planned revascularization.
- Long-term outcomes of patients who underwent mechanical circulatory support therapy in the MOMENTUM 3 trial.
- CARES, a study of the CV safety of febuxostat (Uloric, Takeda) and allopurinol in patients with gout and CV comorbidities.
- A new diabetes-related analysis from the CANTOS trial of the anti-inflammatory therapy canakinumab (Novartis).
- TRIUMPH, a pragmatic trial of a low-dose triple-combination BP-lowering pill for initial treatment of hypertension.
- POISE, which will feature 1-year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery.
- STOP-PAD, a study in patients with CLI to evaluate the safety and efficacy of hSDF-1 plasmid (JVS-100) after open or endovascular revascularization to enhance wound healing.
- A study of device closure vs. medical therapy for secondary prevention in patients with cryptogenic stroke and high-risk patent foramen ovale.
Cardiology Today and Cardiology Today’s Intervention will report live from the sessions. Visit Healio.com/Cardiology during the sessions for breaking news, videos, perspective from experts in the field on major results and announcements, and more.